(56 days)
Yes
The summary explicitly mentions "AiCE (Advanced Intelligent Clear-IQ Engine)" and references predicate devices that include "AiCE Reconstruction Processing Unit for MR".
No
The device is described as a "diagnostic imaging modality" used to "produce cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures" and to "yield information that can be useful in diagnosis." It does not provide therapy or treatment.
Yes
The "Intended Use / Indications for Use" section explicitly states that "Vantage Orian 1.5T systems are indicated for use as a diagnostic imaging modality". It further elaborates that the images produced "yield information that can be useful in diagnosis."
No
The device description explicitly states it is a "1.5 Tesla Magnetic Resonance Imaging (MRI) System" and details hardware components like the magnet, gradient coil, and whole body coil. While it includes software features like noise reduction and AI, it is fundamentally a hardware system with integrated software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is a "diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body." This describes an in-vivo imaging system, not a device used to examine specimens taken from the body (in vitro).
- Device Description: The description details a Magnetic Resonance Imaging (MRI) system, which is a type of medical imaging equipment used to visualize internal structures of the body.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.) or performing tests on specimens outside of the body. The device's function is to generate images of the patient's internal anatomy.
Therefore, the Vantage Orian 1.5T system is an in-vivo diagnostic imaging device, not an in-vitro diagnostic device.
No
The text states "Control Plan Authorized (PCCP) and relevant text Not Found", indicating no explicit mention or approval of a PCCP for this device.
Intended Use / Indications for Use
Vantage Orian 1.5T systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
·Proton density (PD) (also called hydrogen density) ·Spin-lattice relaxation time (T1)
·Spin-spin relaxation time (T2)
·Flow dynamics
·Chemical Shift
Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
Product codes
LNH
Device Description
The Vantage Orian (Model MRT-1550) is a 1.5 Tesla Magnetic Resonance Imaging (MRI) System. The Vantage Orian uses 1.4 m short and 4.1 tons light weight magnet. It includes the Canon Pianissimo™ and Pianissimo Zen technology (scan noise reduction technology). The design of the gradient coil and the whole body coil of the Vantage Orian provides the maximum field of view of 55 x 55 x 50 cm. The Model MRT-1550/ UC, UD, UG, UH, UK, UL, UO, UP includes the XGO gradient system.
This system is based upon the technology and materials of previously marketed Canon Medical Systems MRI systems and is intended to acquire and display cross-sectional transaxial, coronal, sagittal, and oblique images of anatomic structures of the head or body. The Vantage Orian MRI System is comparable to the current 1.5T Vantage Orian MRI System (K202210), cleared September 22, 2020 with the following modifications.
Mentions image processing
Yes, the device is named "Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR" and mentions various imaging parameters and processing techniques like "Compressed SPEEDER", "Exsper (Expanded SPEEDER)", "Fast 3D for SSFP", "Fast 3D for TOF", "Short T2* map (multi echo-UTE)", "Advanced DWI-Diffusion time", "AiCE (Advanced Intelligent Clear-IQ Engine)", "RX/TX Correction plus", "Double Coverage Interleave".
Mentions AI, DNN, or ML
Yes, the device name includes "AiCE Reconstruction Processing Unit for MR", which stands for "Advanced Intelligent Clear-IQ Engine".
Input Imaging Modality
Magnetic Resonance Imaging (MRI)
Anatomical Site
Head or body (specifically Head (brain), MSK (shoulder, elbow, wrist/hand, hip, knee, foot/ankle), Spine (cervical, thoracic, lumbar), Pelvis (soft tissue pelvis, female, prostate), Abdomen (liver, renal, pancreas), Breast, Cardiac listed for AiCE anatomical region expansion).
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Trained physician
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Risk analysis and verification/validation testing conducted through bench testing are included in this submission which demonstrate that the system requirements have been met. Additionally, image quality testing was completed which demonstrated that the subject device meets predetermined acceptance criteria.
MR image quality metrics were performed, utilizing phantom images, to assess Rx/Tx Correction Plus with regards to image homogeneity. It was concluded that Rx/Tx Correction Plus increases the homogeneity of the image compared to the image without intensity correction.
MR image quality metrics were performed, utilizing phantom images, to assess Exper (expanded SPEEDER) maximum acceleration factor of up to six with regards to image distortion, homogeneity, low contrast and SNR. It was confirmed that the distortion due to magnetic field inhomogeneity was reduced by increasing the Exsper acceleration factor.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found. Key metrics mentioned are image homogeneity, distortion, low contrast, and SNR.
Predicate Device(s)
Vantage Orian 1.5T, MRT-1550, V6.0 (K202210)
Reference Device(s)
Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR (K203053), Vantage Orian 1.5T, MRT-1550, V6.0 with AiCE Reconstruction Processing Unit for MR (K202767)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.1000 Magnetic resonance diagnostic device.
(a)
Identification. A magnetic resonance diagnostic device is intended for general diagnostic use to present images which reflect the spatial distribution and/or magnetic resonance spectra which reflect frequency and distribution of nuclei exhibiting nuclear magnetic resonance. Other physical parameters derived from the images and/or spectra may also be produced. The device includes hydrogen-1 (proton) imaging, sodium-23 imaging, hydrogen-1 spectroscopy, phosphorus-31 spectroscopy, and chemical shift imaging (preserving simultaneous frequency and spatial information).(b)
Classification. Class II (special controls). A magnetic resonance imaging disposable kit intended for use with a magnetic resonance diagnostic device only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
Image /page/0/Picture/10 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and the word "ADMINISTRATION" in a smaller font size below that.
Canon Medical Systems Corporation % Ms. Janine F. Reyes Manager, Regulatory Affairs Canon Medical Systems USA, INC. 2441 Michelle Drive TUSTIN CA 92780
Re: K211633
Trade/Device Name: Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR Regulation Number: 21 CFR 892.1000 Regulation Name: Magnetic resonance diagnostic device Regulatory Class: Class II Product Code: LNH Dated: May 25, 2021 Received: May 27, 2021
Dear Ms. Reyes:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
July 22, 2021
1
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
For
Thalia T. Mills, Ph.D. Director Division of Radiological Health OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
510(k) Number (if known)
Device Name
Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR
Indications for Use (Describe)
Vantage Orian 1.5T systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
·Proton density (PD) (also called hydrogen density) ·Spin-lattice relaxation time (T1)
·Spin-spin relaxation time (T2)
·Flow dynamics
·Chemical Shift
Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
| Type of Use (Select one or both, as applicable) | ||||
|---|---|---|---|---|
| × Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff @fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) SUMMARY
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of Safe Medical Device Act 1990 and 21 CFR § 807.92
1. CLASSIFICATION and DEVICE NAME
| Classification Name: | Magnetic Resonance Diagnostic Device |
|---|---|
| Regulation Number: | 90-LNH (Per 21 CFR § 892.1000) |
| Trade Proprietary Name: | Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction |
| Processing Unit for MR | |
| Model Number: | MRT-1550 |
2. SUBMITTER'S NAME
Canon Medical Systems Corporation 1385 Shimoishigami Otawara-Shi, Tochigi-ken, Japan 324-8550
3. OFFICIAL CORRESPONDENT
Naofumi Watanabe Senior Manager, Regulatory Affairs and Vigilance Canon Medical Systems Corporation
4. CONTACT PERSON, U.S. AGENT and ADDRESS
Contact Person
Janine F. Reyes Manager, Regulatory Affairs Canon Medical Systems USA, Inc. 2441 Michelle Drive, Tustin, CA 92780 Phone: (714) 669-7853 Fax: (714) 730-1310 E-mail: jfreyes@us.medical.canon
Official Correspondent/U.S. Agent
Paul Biggins Senior Director, Regulatory Affairs Canon Medical Systems USA, Inc. 2441 Michelle Drive, Tustin, CA 92780 Phone: (714) 730-7808 Fax: (714) 730-1310 E-mail: pbiggins@us.medical.canon
4
5. MANUFACTURING SITE
Canon Medical Systems Corporation 1385 Shimoishigami Otawara-shi, Tochigi 324-8550, Japan
-
- ESTABLISHMENT REGISTRATION 9614698
-
- DATE PREPARED May 25, 2021
8. DEVICE NAME
Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR
9. TRADE NAME
Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR
10. CLASSIFICATION NAME
Magnetic Resonance Diagnostic Device (MRDD)
11. CLASSIFICATION PANEL
Radiology
12. DEVICE CLASSIFICATION
Class II (per 21 CFR 892.1000, Magnetic Resonance Diagnostic Device)
13. PRODUCT CODE
90-LNH
14. PREDICATE DEVICE
Predicate Device (system): Vantage Orian 1.5T, MRT-1550, V6.0 (K202210) Reference Devices: Vantage Orian 1.5T, MRT-1550, V7.0 with AiCE Reconstruction Processing Unit for MR (K203053) and Vantage Orian 1.5T, MRT-1550, V6.0 with AiCE Reconstruction Processing Unit for MR (K202767).
| System | Subject Device | Predicate Device | Reference Device | Reference Device |
|---|---|---|---|---|
| Vantage Orian 1.5T, | ||||
| MRT-1550, V7.0 with | ||||
| AiCE Reconstruction | ||||
| Processing Unit for MR | Vantage Orian 1.5T, | |||
| MRT-1550, V6.0 | Vantage Orian 1.5T, | |||
| MRT-1550, V7.0 with | ||||
| AiCE Reconstruction | ||||
| Processing Unit for MR | Vantage Orian 1.5T, | |||
| MRT-1550, V6.0 with | ||||
| AiCE Reconstruction | ||||
| Processing Unit for MR | ||||
| Marketed | ||||
| By | Canon Medical Systems | |||
| USA, Inc. | Canon Medical Systems | |||
| USA, Inc. | Canon Medical Systems | |||
| USA, Inc. | Canon Medical Systems | |||
| USA, Inc. | ||||
| 510(k) | ||||
| Number | This Submission | K202210 | K203053 | K202767 |
| Clearance | ||||
| Date | September 22, 2020 | December 2, 2020 | January 15, 2021 |
5
Image /page/5/Picture/0 description: The image shows the logo for Canon Medical Systems USA, INC. The word "Canon" is in red, and the words "CANON MEDICAL SYSTEMS USA, INC." are in black. The logo is simple and clean, and it is likely used on the company's website and marketing materials. The logo is likely used to promote the company's products and services.
15. REASON FOR SUBMISSION
Modification of a cleared device
16. SUBMISSION TYPE
Traditional 510(k) Premarket Notification
17. DEVICE DESCRIPTION
The Vantage Orian (Model MRT-1550) is a 1.5 Tesla Magnetic Resonance Imaging (MRI) System. The Vantage Orian uses 1.4 m short and 4.1 tons light weight magnet. It includes the Canon Pianissimo™ and Pianissimo Zen technology (scan noise reduction technology). The design of the gradient coil and the whole body coil of the Vantage Orian provides the maximum field of view of 55 x 55 x 50 cm. The Model MRT-1550/ UC, UD, UG, UH, UK, UL, UO, UP includes the XGO gradient system.
This system is based upon the technology and materials of previously marketed Canon Medical Systems MRI systems and is intended to acquire and display cross-sectional transaxial, coronal, sagittal, and oblique images of anatomic structures of the head or body. The Vantage Orian MRI System is comparable to the current 1.5T Vantage Orian MRI System (K202210), cleared September 22, 2020 with the following modifications.
18. SUMMARY OF CHANGE(S)
This submission is to report the following changes:
Summary of Hardware Changes: (subject modification)
- Gradient amplifier for XGO is applied (K203053). Maximum gradient amplitude (per axis) [mT/m], maximum slew rate [mT/m/ms], and rise time [ms] changes:
- O Increased Gradient Strength: increased gradient strength from 34 [mT/m] to 45 [mT/m].
- O Maximum Slew Rate Change: maximum slew rate of gradient field was changed from 155 [mT/m/ms] to 200 [mT/m/ms].
- O Rise Time Change: rise time changed from 0.220 ms to 0.225 ms.
- Gradient coil minor change: minor change to Zch wire position.
Summary of Software Changes:
- . FASE 3D/FFE3D:
- o Compressed SPEEDER (Compressed Sensing 3D): This application allows acceleration factors for shorter scan times or higher resolution in FASE3D and FFE3D in addition to FSE2D, imaging based upon the principle of compressed sending in combination with parallel imaging (K203053).
- FE 3D: ●
- o Fat Fraction Quantification: Data is acquired with several different TE and provides PDFF image, R2* image, water image, fat image, in phase image and out of phase image (total 6 kind of images). Proton Density Fat Fraction data and R2* data is supporting fat content ratio (K203053).
6
- EPI: ●
- ୍ Exsper (Expanded SPEEDER): This application allows reducing scan time for diffusion imaging, Exsper technique scans center of k-space data but surrounding area data is undersampled. It finds coefficient from the data of center k-space and synthesizes the undersampled data by using surrounding data and the coefficient (K203053).
- ୍ Exsper (Expanded SPEEDER): The number of maximum acceleration factor changes to 6 (subject modification).
- FFE 3D:
- o Fast 3D for SSFP: This application allows Fast 3D mode in SSFP 3D sequences, which helps to reduce the scan time by about 50% (K203053).
- 3D Time-of-Flight (TOF): ●
- o Fast 3D for TOF: This application allows reducing the scan time while maintaining image quality by up to half for TOF images by adjusting data acquisition ratio (K203053).
- Short T2* map (multi echo-UTE): UTE imaging is available for acquisition of different TE data for T2* mapping of tissues with short T2* (K203053).
- Advanced DWI-Diffusion time: Various diffusion times are available (K203053).
- AiCE (Advanced Intelligent Clear-IQ Engine):
- o AiCE anatomical region expansion: Head (brain), MSK (shoulder, elbow, wrist/hand, hip, knee, foot/ankle), Spine (cervical, thoracic, lumbar), Pelvis (soft tissue pelvis, female, prostate), Abdomen (liver, renal, pancreas), Breast, Cardiac (K202767).
- o AiCE noise estimation improvement: By taking into consideration g-factor, noise can be removed from the part where g-factor was considered (K203053).
- RX/TX Correction plus: The intensity nonuniformity due to the sensitivity distribution of the coil during transmission and reception can be corrected. The RX/TX Correction plus function can be used for the chest, extremities, and joints, for which the RX/TX Correction function cannot be used (subject modification).
- Double Coverage Interleave: The planned slices are divided into coverages at intervals of N-1 slices, where N is the number of coverages, and then the coverages are excited sequentially. In addition, Interleave acquisition is applied in each coverage (subject modification).
Summary of Accessory Changes:
- RF Coils: The following RF coils, previously cleared by the OEM (Quality Electrodynamics, LLC) via 510(k) premarket notification K200477, are added:
- Shape Coil, MJAB-207A (subject modification) o
- Shape Coil W, MJAB-217A (subject modification) O
- Patient Pads: surface material change.
- Respiratory Gating System Belt: material change.
7
Summary of labeling Change:
- M-Power: "M-Power" marketing name is removed (subject modification). ●
19. SAFETY PARAMETERS
| Item | Subject Device:
Vantage Orian 1.5T,
MRT-1550, V7.0 | Predicate Device:
Vantage Orian 1.5T,
MRT-1550, V6.0 | Notes |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|-------|
| Static field strength | 1.5T | 1.5T | Same |
| Operational Modes | Normal and 1st Operating Mode | Normal and 1st Operating Mode | Same |
| i. Safety parameter display | SAR, dB/dt | SAR, dB/dt | Same |
| ii. Operating mode access
requirements | Allows screen access to 1st level
operating mode | Allows screen access to 1st level
operating mode | Same |
| Maximum SAR | 4W/kg for whole body (1st
operating mode specified in IEC
60601-2-33:
2010+A1:2013+A2:2015) | 4W/kg for whole body (1st
operating mode specified in IEC
60601-2-33:
2010+A1:2013+A2:2015) | Same |
| Maximum dB/dt | 1st operating mode specified in IEC
60601-2-33:
2010+A1:2013+A2:2015 | 1st operating mode specified in IEC
60601-2-33:
2010+A1:2013+A2:2015 | Same |
| Potential emergency
condition and means
provided for shutdown | Shutdown by Emergency Ramp
Down Unit for collision hazard for
ferromagnetic objects | Shutdown by Emergency Ramp
Down Unit for collision hazard for
ferromagnetic objects | Same |
20. IMAGING PERFORMANCE PARAMETERS
No change from the previous predicate submission, K202210.
21. INDICATIONS FOR USE
Vantage Orian 1.5T systems are indicated for use as a diagnostic imaging modality that produces crosssectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.
MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:
- Proton density (PD) (also called hydrogen density)
- Spin-lattice relaxation time (T1) ●
- Spin-spin relaxation time (T2)
- Flow dynamics
- Chemical Shift
Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.
8
Made For life
22. SUMMARY OF DESIGN CONTROL ACTIVITIES
Risk Management activities for new software functionalities and pulse sequences are included in this submission. The test methods used are the same as those submitted in the previously cleared submission of the predicate device, Vantage Orian 1.5T, MRT-1550, V6.0 (K202210). A declaration of conformity with design controls is included in this submission.
23. SAFETY
This device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards.
This device is based upon the same technologies, materials and software as the predicate device. Risk activities were conducted in concurrence with established medical device development standards and guidance. Additionally, testing was done in accordance with applicable recognized consensus standards published by the International Electrotechnical Commission (IEC) for medical devices and the National Electrical Manufacturers Association (NEMA):
LIST OF APPLICABLE STANDARDS
- ANSI AAMI ES60601-1:2005/(R)2012 ● and A1:2012
- IEC60601-1-2 (2014)
- IEC60601-1-6 (2010), Amd.1 (2013)
- IEC60601-2-33 (2010), Amd.1 (2013), Amd.2 (2015)
- . IEC60825-1 (2007)
- IEC62304 (2006), Amd.1 (2015) ●
- IEC62366 (2007), Amd.1 (2014)
- NEMA MS 1 (2008)
- NEMA MS 2 (2008)
- NEMA MS 3 (2008)
- NEMA MS 4 (2010)
- NEMA MS 5 (2018)
24. TESTING
Risk analysis and verification/validation testing conducted through bench testing are included in this submission which demonstrate that the system requirements have been met. Additionally, image quality testing was completed which demonstrated that the subject device meets predetermined acceptance criteria.
MR image quality metrics were performed, utilizing phantom images, to assess Rx/Tx Correction Plus with regards to image homogeneity. It was concluded that Rx/Tx Correction Plus increases the homogeneity of the image compared to the image without intensity correction.
MR image quality metrics were performed, utilizing phantom images, to assess Exper (expanded SPEEDER) maximum acceleration factor of up to six with regards to image distortion, homogeneity, low contrast and SNR. It was confirmed that the distortion due to magnetic field inhomogeneity was reduced by increasing the Exsper acceleration factor.
Software Documentation for a Moderate Level of Concern, per the FDA guidance document, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document" issued on May 11, 2005, is also included as part of this submission.
9
25. SUBSTANTIAL EQUIVALENCE
Canon Medical Systems Corporation believes that the Vantage Orian 1.5T, MRT-1550, V7.0 Magnetic Resonance Imaging (MRI) System is substantially equivalent to the previously cleared predicate device, Vantage Orian 1.5T, MRT-1550, V6.0, referenced in this submission.
Canon Medical Systems Corporation believes that the changes incorporated into the Vantage Orian 1.5T, MRT-1550, V7.0 are substantially equivalent to the previously cleared predicate device.
26. CONCLUSION
The modifications incorporated into the Vantage Orian 1.5T, MRT-1550, V7.0 do not change the indications for use or the intended use of the device. Based upon bench testing, volunteer clinical imaging, successful completion of software validation and application of risk management and design controls, it is concluded that the subject device is safe and effective for its intended use.